A new strategy for isolating oligodendrocyte progenitor cells from the human brain may advance the goal of therapeutic remyelination.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Franklin, R.J. & ffrench-Constant, C. Nat. Rev. Neurosci. 9, 839–855 (2008).
Sim, F.J. et al. Nat. Biotechnol. 29, 934–941 (2011).
Miller, R.H. Prog. Neurobiol. 67, 451–467 (2002).
Nishiyama, A. Neuroscientist 13, 62–76 (2007).
Raff, M.C., Miller, R.H. & Noble, M. Nature 303, 390–396 (1983).
Pringle, N., Collarini, E.J., Hart, I.K., Raff, M.C. & Richardson, W.D. Ann. NY Acad. Sci. 633, 160–168 (1991).
Windrem, M.S. et al. Cell Stem Cell 2, 553–565 (2008).
Windrem, M.S. et al. Nat. Med. 10, 93–97 (2004).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Miller, R., Tesar, P. Tracking down the human myelinating cell. Nat Biotechnol 29, 881–883 (2011). https://doi.org/10.1038/nbt.2004
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2004